Cost Savings Associated With Rifaximin for Diarrhea-Predominant Irritable Bowel SyndromeM. PimentelMd MSEd MSc Epi Philip SchoenfeldM. PurdyP. GilbertA. R. MagarThe American Journal of Managed Care
Cost Savings Associated With Rifaximin for Diarrhea-Predominant Irritable Bowel Syndrome | Page 2Mark PimentelPhilip SchoenfeldMSEdMSc EpiChristopher H. PurdyMAColleen GilbertPharmDand Raf Magar
This analysis estimated the cost effectiveness of rifaximin-alpha 550 mg twice daily plus lactulose versus lactulose alone in United Kingdom (UK) cirrhotic patients with OHE.Berni, EllenMurphy, DanielWhitehouse, JamesConway, Petedi Maggio, PaolaCurrie, Craig J.Poole, Chris...
InsuranceDrug CoverageIncreasing drug prices lead to payer coverage restrictions, which limit access to therapy. We assessed the cost effectiveness of rifaximin in management of patients with irritable bowel syndrome with diarrhea (IBS-D) under common payer coverage restrictions and determined the maximum...